Skip to main content

Abstract

Objective:

Catatonia is a debilitating psychomotor disorder. Previous neuroimaging studies have used small samples with inconsistent results. The authors aimed to describe the structural neuroradiological abnormalities in clinical magnetic resonance imaging (MRI) brain scans of patients with catatonia, comparing them with scans of psychiatric inpatients without catatonia. They report the largest study of catatonia neuroimaging to date.

Methods:

In this retrospective case-control study, neuroradiological reports of psychiatric inpatients who had undergone MRI brain scans for clinical reasons were examined. Abnormalities were classified by lateralization, localization, and pathology. The primary analysis was prediction of catatonia by presence of an abnormal MRI scan, adjusted for age, sex, Black race-ethnicity, and psychiatric diagnosis.

Results:

Scan reports from 79 patients with catatonia and 711 other psychiatric inpatients were obtained. Mean age was 36.4 (SD=17.3) for the cases and 44.5 (SD=19.9) for the comparison group. Radiological abnormalities were reported in 27 of 79 cases (34.2%) and in 338 of 711 in the comparison group (47.5%) (odds ratio [OR]=0.57, 95% confidence interval [CI]=0.35, 0.93; adjusted OR=1.11, 95% CI=0.58, 2.14). Among the cases, most abnormal scans had bilateral abnormalities (N=23, 29.1%) and involved the forebrain (N=25, 31.6%) and atrophy (N=17, 21.5%).

Conclusions:

Patients with catatonia were commonly reported to have brain MRI abnormalities, which largely consisted of diffuse cerebral atrophy rather than focal lesions. No evidence was found that these abnormalities were more common than in other psychiatric inpatients undergoing neuroimaging, after adjustment for demographic variables. Study limitations included a heterogeneous control group and selection bias in requesting scans.
Catatonia is a psychomotor syndrome characterized by a state of reduced responsiveness and inability to move normally despite complete physical capacity (1). It is recognized to occur in a variety of mental disorders and reportedly affects 5%−18% of patients with acute severe psychiatric illness (2). It may also occur in the context of many neurological and general medical disorders (3). It is a serious and debilitating condition, associated with multiple life-threatening complications, yet it is often underdiagnosed (4).
Catatonia was previously classified as a subtype of schizophrenia and organic mental disorders; however, the ICD-11 now recognizes catatonia as a distinct neuropsychiatric syndrome, and DSM-5 permits a diagnosis of catatonia in the context of any psychiatric or general medical disorder (5, 6). Despite catatonia’s diverse etiologies, the generally positive response to benzodiazepines regardless of the underlying cause provides some evidence for a unified disorder (7). Nonetheless, the pathophysiology of catatonia has remained elusive: theories about the neurotransmitters GABA, dopamine, and glutamate, as well as hypotheses regarding phenomenology, neural networks, and neuroinflammation, remain unconfirmed (813).
Findings from neuroimaging studies in catatonia have been inconsistent. Focal lesions associated with catatonia have been identified in sites as diverse as the frontal lobes, parietal lobes, temporal lobes, basal ganglia, anterior cingulate gyrus, thalamus, pons, and cerebellum (14). A recent systematic review reported that most patients with catatonia who had abnormalities had diffuse and focal white matter lesions, occurring in many different regions (15). Furthermore, functional imaging frequently showed frontal, temporal, or basal ganglia hypoperfusion, and structural imaging mostly showed diffuse cerebral atrophy (15). However, most brain imaging studies in catatonia are case reports or series describing findings in a small sample of patients. Although these studies are of interest, the samples are not large enough to identify patterns, they are prone to selection bias, and the studies have often lacked comparison groups. To date, no studies have explored the structural neuroimaging findings in a large population of patients with catatonia with an appropriate comparison group.
Here we present a study that utilized a large data set to describe neuroimaging findings in clinical magnetic resonance imaging (MRI) reports, comparing them with findings for psychiatric patients without catatonia. We had two specific objectives: to identify the distribution of abnormalities among patients with catatonia in terms of laterality, localization, and pathology and to compare the frequency of such MRI abnormalities in psychiatric patients with and without catatonia.

Methods

Study Design

This study was a case-control study comparing neuroradiological abnormalities in clinical reports of MRI brain scans of patients with catatonia with those of psychiatric patients without catatonia. Anonymized electronic health care records from patients seen in the South London and Maudsley National Health Service Foundation Trust (SLaM), London, were accessed through the Clinical Records Interactive Search (CRIS). The CRIS system has previously been described (16) and is approved by the Oxfordshire C Research Ethics Committee (ref. 18/SC/0372). This specific study was approved by the CRIS Oversight Committee (ref. 17–102).

Data Availability

Data are owned by a third party, Maudsley Biomedical Research Centre Clinical Records Interactive Search (CRIS) tool, which provides access to anonymized data derived from SLaM electronic medical records. These data can be accessed only by permitted individuals from within a secure firewall (i.e., the data cannot be sent elsewhere). (For more information, contact [email protected].)

Outcome

Cases of catatonia were defined as having a clinician diagnosis of catatonia and at least two features on the Bush-Francis Catatonia Screening Instrument, a reliable and validated instrument for the detection of catatonia (7, 17, 18), as described in previous work by this group (19). Because this was a heterogeneous population with a range of diagnoses, the comparison group comprised all patients admitted to psychiatric wards in the Trust who had never had a catatonia diagnosis. All patients with catatonia had also been psychiatric inpatients.

Exposure

The exposure was an abnormal MRI scan, as judged by the reporting neuroradiologist. The clinical scanner was a 1.5 Tesla GE HDx, with scans collected for clinical reporting, including high-resolution T1-weighted, T2-weighted, and FLAIR sequences without contrast. The electronic health care records and MRI clinical radiological reports were extracted, where available, from the electronic records for all patients admitted to a hospital ward who met the selection criteria described above. The following data were extracted from structured fields in the records: age at index date, sex, race-ethnicity, involuntary detention within 2 weeks following the index date, and primary ICD-10 diagnosis. The index date for patients with catatonia was the date of the first identified catatonic episode; for the comparison group, the date of hospital admission was used as the index date. When a diagnosis had been made prior to the index date, the most recent diagnosis prior to the index date was used; when this was not available, the earliest diagnosis up to 6 months after the index date was used. MRI scans were reported by consultant neuroradiologists, of whom there are currently eight. Scans that occurred at any time before the index date or within 90 days after the index date were included. Scans obtained more than 90 days after the index date were excluded on pragmatic grounds, because there was a higher risk that they included abnormalities that had developed after the index illness. Where there were multiple scans available for one patient, the scan that was nearest to the index date was used. The procedure is illustrated in Figure 1.
FIGURE 1. Selection of patients for the catatonia group and for a comparison group of other psychiatric inpatients
All available MRI reports from 2008 to 2018 were compiled in a spreadsheet. The reports were categorized and numerically coded for the presence of abnormalities by their anatomical location, pathological description, and lateralization. In scans with multiple abnormalities, each abnormality was coded separately by these criteria to minimize loss of data. Extracranial abnormalities were excluded. All reports were evaluated independently by two investigators (R.J. and R.T.), who were blinded to the diagnostic groups and each other’s assessments. Where there was disagreement, a third investigator (J.P.R.) arbitrated. The study size was determined pragmatically based on the number of available cases.
Following data collection, small cell sizes were merged based on a priori relationships between categories blind to group membership. The anatomical areas were merged based on embryological brain structure, and the pathologies were merged according to the main underlying mechanism.

Confounders

The potential confounders considered were age on date of scan, sex (male or female), Black race-ethnicity, and diagnostic group. We chose to adjust for these potential confounders because they have previously been associated with differences in brain MRI findings (2024) and have been associated with risk of catatonia in prior studies (2528). Ethnicity categories were grouped according to the preferred categories of the United Kingdom Office for National Statistics (29). Mixed or multiple ethnic groups were combined with “other” ethnic group to avoid small cell sizes. Primary diagnoses were grouped as organic and neurodevelopmental disorders (ICD-10 codes F00–F09, F70–89, F90, F95, and non-F codes), schizophrenia and related disorders (F20–F29), mood disorders (F30–F39), neurotic disorders (F40–F59), personality and behavioral disorders (F50–F69, F91–F94, and F98), and substance use disorders (F10–F19).

Statistical Analysis

We investigated whether having an abnormal MRI scan was associated with greater odds of reporting catatonia; we used univariable and multivariable logistic regression models adjusted for age, sex, and race-ethnicity.
Given the differing proportions of organic or neurodevelopmental diagnoses across the groups, we conducted a sensitivity analysis in which we excluded these diagnoses. As a secondary analysis, among the abnormal scans, we conducted a logistic regression for catatonia based on the number of abnormalities per scan, adjusted for age, sex, Black race-ethnicity, and diagnostic group.
We analyzed lateralization, anatomical location, and pathology by the number of scans that had at least one abnormality in the specified category. This was done to avoid scans with many abnormalities excessively weighting the analyses. To calculate the differences between proportions having different categories of abnormalities, we used Fisher’s exact test, because there were numerous small cell sizes.
Missing data were assumed to be missing at random. Therefore, to explore the impact of missing data on our estimates, as a sensitivity analysis, we imputed missing exposure data for participants with complete outcome data by using multiple imputation by chained equations. We imputed 20 data sets using all variables included in the models, as well as a number of auxiliary variables that were associated either with one of the variables of interest or with missingness of one of the variables of interest. The variables included in the final imputation model were abnormal scan, catatonia, age at scan, sex, Black race-ethnicity, diagnostic group, electroconvulsive therapy use within 2 weeks after index, age at index (either onset of catatonia or hospital admission), date of birth, date of scan, diastolic blood pressure, systolic blood pressure, date of death, time from referral to index date, time from index date to documentation, end date of catatonic episode, Health of the Nation Outcome Scale (HoNOS) score, HoNOS date, index date, duration of admission, Mini-Mental State Exam score, episode order, death within follow-up, involuntary detention, and validity of MRI report. (The observed and imputed data are compared in Table S1 in the online supplement to this article.) The analysis used Stata MP, version 15.1.
This article was written according to the STROBE guidelines (30). (The STROBE checklist is available in Table S2 in the online supplement.)

Results

Participants

Of 1,456 patients with catatonia and 24,956 patients in the comparison group, complete MRI scan reports were extracted for 790 subjects, who had a total of 816 scans. After extraction of one scan per patient, there were 79 scans in the catatonia group (5.4% of all patients with catatonia) and 711 scans in the comparison group (2.8% of all patients in the comparison group), as illustrated in Figure 1. A total of 188 included scans were conducted prior to the index date, and 602 were conducted on or after the index date. The median time from index date to scan was 27 days (interquartile range [IQR]=5 to 48), and the range was –2,679 to 90 days. Sixty-nine scans were conducted within 2 weeks of the index date.

Missing Data

A scan result was missing for 25,622 (97.0%) participants, age at index for 1,904 (7.2%), sex for four (0.0%), and race-ethnicity for 393 (1.5%). Patients of Black race-ethnicity appeared more likely to have an MRI scan, but the groups were similar in terms of age and sex (see Table S3 in online supplement).

Demographic and Disease-Related Characteristics

Table 1 summarizes the demographic and disease-related data of the participants in this study. Mean age at the time of the scan was 36.4 years (SD=17.3; range, 10–78) for the catatonia group and 44.5 years (SD=19.9; range, 7–93) for the comparison group. Handedness of subjects is not available in this data set.
TABLE 1. Characteristics of patients with catatonia and a comparison group of other psychiatric inpatients
 Catatonia group (N=79)Comparison group (N=711)
CharacteristicN%N%
Sex    
 Female3544.331644.4
 Male4455.739555.6
Race-ethnicity    
 White2126.638954.7
 Asian, Asian British45.1456.3
 Black, African, Caribbean, Black British4962.022631.8
 Mixed, multiple ethnic groups11.3121.7
 Other33.8324.5
 Not stated11.371.0
Primary diagnosis    
 Organic or neurodevelopmental disorder33.812417.4
 Schizophrenia or related disorder5063.326637.4
 Mood disorder1220.114320.1
 Neurotic disorder33.8314.4
 Personality or behavioral disorder56.3314.4
 Substance use disorder22.5456.3
 Not stated45.1699.7
Involuntary detention5569.645964.6

Abnormalities

In total, 365 of 790 scans (46.2%) were reported as abnormal. As shown in Table 2, 34.2% of the catatonia group had an abnormal scan, compared with 47.5% of the comparison group. In the unadjusted complete-case analysis, having an abnormal MRI scan was associated with lower odds of a diagnosis of catatonia (odds ratio [OR]=0.57, 95% confidence interval [CI]=0.35, 0.93, p=0.03). After adjustment for confounders (age, sex, Black race-ethnicity, and diagnostic group), there was no longer evidence of an association (OR=1.11. 95% CI=0.58, 2.14, p=0.75). In sensitivity analyses run on imputed data sets, the results were consistent with those of complete case analyses (OR=0.92, 95% CI=0.48, 1.74; adjusted OR=1.30, 95% CI=0.53, 3.20). (Abnormalities by diagnostic group are reported in Table S4 in the online supplement.)
TABLE 2. Number of normal and abnormal scans in the catatonia and comparison groups
 Scan normalScan abnormal 
GroupN%N%Total N
Catatonia5265.82734.279
Comparison37352.533847.5711
Total42553.836546.2790
Among the scans reported as abnormal, there were between one and 10 abnormalities. In the patients with catatonia, the median number of abnormalities was two (IQR=1–3). In the comparison group, the median number of abnormalities was two (IQR=1–4). The unadjusted OR for catatonia diagnosis as predicted by the number of abnormalities was 0.84 (95% CI=0.65, 1.08, p=0.17). After adjustment for age, sex, Black race-ethnicity, and diagnostic group, the OR was 0.96 (95% CI=0.75, 1.23, p=0.74).

Lateralization

Table 3 shows that most abnormal scans had at least one bilateral abnormality in both the catatonia and the comparison groups. We found no evidence of difference in lateralization of abnormalities between the groups (p=0.98).
TABLE 3. Abnormalities by lateralization, localization, and pathology in the catatonia and comparison groupsa
 Catatonia group (N=79)Comparison group (N=711)
AbnormalityN%N%
Lateralization    
 Midline33.8436.1
 Bilateral2329.130042.2
 Right67.6679.4
 Left56.37410.4
Anatomical location    
 Midbrain071.0
 Forebrain2531.631243.9
 Hindbrain911.48211.5
 White matter tract11.3253.5
 Nonbrain11.381.1
Pathology    
 Atrophy1721.521029.5
 Small vessel disease911.413919.6
 White matter lesion810.17410.4
 Stroke22.5588.2
 Unspecified focal lesion22.5172.4
 Gliosis and encephalomalacia11.3473.6
 Prominent perivascular spaces11.3111.6
 Vascular abnormality11.360.8
 Ectopia11.340.6
 Hypoplasia11.310.1
 Contusion11.3182.5
 Cyst0101.4
 Demyelination060.8
 Cavum050.7
 Wallerian degeneration040.6
 Tumor020.3
 Midline shift020.3
 Enlargement020.3
 Malformation of cortical development020.2
 Extra-axial hemorrhage010.1
 Sclerosis010.1
 Ulegyria010.1
 Progressive multifocal leukoencephalopathy010.1
 Absence010.1
a
Number of scans in each group that had at least one abnormality with the specified properties. Each scan may appear in more than one category; e.g., a scan may have a midline and a right-sided abnormality.

Anatomical Location

Abnormalities were reported across various brain regions, as shown in Table 3. Most abnormalities were in the forebrain in both groups. We found no evidence of differences in anatomical location of abnormalities between the groups (p=0.73). In the catatonia group, among 25 scans with forebrain abnormalities, the specific location of the abnormalities was diffuse cerebral (N=18), frontal (N=7), parietal (N=4), temporal (N=3), occipital (N=1), basal ganglia (N=1), thalamus (N=1), pituitary gland (N=1), and optic nerve (N=1). (Some scans had more than one abnormality.) In terms of the nine scans with hindbrain abnormalities in the catatonia group, the specific locations were the cerebellum (N=6) and pons (N=3).

Pathology

The numbers of scans reporting different categories of pathology are reported in Table 3. The most common pathologies in both groups were brain atrophy and small vessel disease. Additionally, the scans of the catatonia group showed similar frequencies of white matter lesions and small vessel disease. There was no evidence of a difference in pathology of abnormalities between the groups (p=0.75).

Discussion

Neuroimaging abnormalities in patients with catatonia have previously been described in case reports and other studies with small sample sizes, often without a comparison group. This study used a large data set to describe common structural neuroimaging findings in patients with catatonia and compared these with findings for psychiatric patients without catatonia.
In terms of descriptive data, we found that MRI abnormalities were commonly reported in individuals with catatonia who had a scan, being present in 27 of 79 scans (34%). It was common for there to be more than one abnormality in each scan. Most abnormal scans had at least one abnormality reported that was bilateral (23 of 27), that affected the forebrain (25 of 27, of which 18 had a diffuse cerebral distribution), and that involved atrophy (17 of 27), although some of these scans also had other types of abnormalities reported. However, when we compared the scans between the groups with and without catatonia, we found no differences in the proportion of scans reported to have an abnormality, after adjustment for age, sex, Black race-ethnicity, and diagnostic group. Secondary analyses also found no evidence for a difference in the number of abnormalities, lateralization, anatomical location, or pathology.
To our knowledge, this is the largest study of catatonia neuroimaging published to date (15). It also had the advantage of representing patients with catatonia across a range of underlying disorders, and it had an appropriate comparison group of psychiatric inpatients without catatonia.
However, there are a number of evident limitations, many inherent to the use of electronic health care records. The most important bias is related to the fact that our patients with neuroimaging were likely to be unrepresentative of all psychiatric inpatients because of the various reasons that they may have been referred for a scan. The reasons for ordering a scan were not available and are likely to differ between the catatonia and the comparison groups, and this would potentially lead to a selection bias. The characteristics of the comparison group have been shown to have a substantial effect on outcomes in studies of neuroimaging in psychiatric patients (31). When a patient did not have an MRI scan, this was generally because it was not requested by the clinician. There is no consensus on whether many groups of psychiatric patients should undergo neuroimaging, but there is evidence that patients who are older and who are suspected to have organic diagnoses are more likely to be referred for neuroimaging (32, 33).
In terms of missing data, on occasion, an MRI scan may have been performed in another hospital, it may have been performed outside the window for this study, or the patient’s lack of cooperation meant that no useful data could be extracted from the scan. Sex and race-ethnicity were occasionally missing (for 0.02% and 1.5% of patients, respectively) in the overall data set, and this was due to an absence of administrative coding of this information in the patient records. Although our sensitivity analysis using multiple imputation was likely to provide a more accurate estimate than complete-case analysis, the model was not able to include all the variables that would ideally be present to assert a missing-at-random hypothesis (such as the presence of focal neurological signs, pre-existing neurological disorders, seizures, or head injury) (32), and thus it is likely that it was not a wholly adequate method of dealing with the missing data.
In terms of confounding, we were able to adjust our analysis for demographic variables, but there were likely to have been other relevant variables (such as cardiovascular risk factors or cognitive function) for which data were not available. Neuroradiologists sometimes reported findings differently and likely had different thresholds for what was worthy of mention. These reports may have been biased by the clinical information presented and the questions asked when the scan was requested. This may in part explain why the proportion of individuals with catatonia with an abnormal MRI scan is somewhat lower than in some previous smaller studies. Medda et al. (34) described 26 patients with catatonia resistant to benzodiazepine treatment finding that the computed tomography (CT) or MRI scan was abnormal in 17 (65%, 95% CI=44%, 83%). Smith et al. (28) examined the MRI scans of 31 patients with catatonia, finding abnormalities in at least 18 (58%, 95% CI=39%, 75%). It is possible that our study has provided a more conservative estimate, because its larger size means it was less susceptible to reporting bias.
There is, however, some consistency with other structural neuroimaging studies in terms of the type of abnormalities. Three other studies have shown extensive or generalized atrophy (or its proxy, enlarged cerebrospinal fluid spaces) as the most common neuroimaging abnormality (28, 34, 35). A large number of case reports of focal lesions associated with catatonia have been reported, but most of these cases are of diffuse or multiple abnormalities (15). Taken together, our findings support a weight of evidence that catatonia is associated with dysfunction of brain networks, rather than being the product of damage to isolated brain regions (10). This is consistent with a quantitative study of MRI images that found reduced gray matter volumes in individuals with catatonia in areas within the frontothalamic and corticostriatal networks (36).
However, when we examined the comparison to psychiatric patients without catatonia, we found no evidence of a difference in the proportion of abnormal scan reports after adjustment for demographic variables. To our knowledge, no prior studies have compared clinical neuroradiological reports of MRI scans in patients with catatonia and in a psychiatric comparison group. Two studies conducted this analysis using CT scan results, but one had just five patients with catatonia (35), and the other focused solely on cerebellar atrophy (37). These findings emphasize the high rate of brain abnormalities in patients with psychiatric disorders, especially schizophrenia and other neuropsychiatric conditions severe enough to require admission, and the need for a psychiatric comparison group in studies of catatonia. Previous work with data from the same center found that only 12.3% of MRI scans were abnormal; however, the mean age in that sample was 26 (compared with 44.5 for our comparison group), and all were under evaluation for first-episode psychosis (38). It seems likely that the older age and greater disease severity of our comparison group led to the detection of more abnormalities, but it is notable that, even after the analysis adjusted for age, there was no evidence that individuals with catatonia were more likely to have an abnormal MRI scan. Adjustment or matching for factors such as psychopathology or neurological signs might be helpful.

Conclusions

Patients with catatonia commonly had MRI scan abnormalities reported, most frequently diffuse atrophy, but there was no evidence that such abnormalities occurred at a higher frequency among these patients, compared with other psychiatric inpatients. This finding is consistent with there being a basic neurological vulnerability to the condition, which relapses and remits, but which may be specifically driven by metabolic or physiological dysfunction. Researchers should consider the benefits of using large clinical samples to study patients with relatively rare and hard-to-recruit conditions, such as catatonia, while mitigating the lack of systematic detail inherent in the qualitative neuroradiological evaluation of clinical MRI scans. However, use of routine health care records has notable limitations, including heterogeneous control groups, selection bias, and varying reporting thresholds from radiologists. Quantitative volumetric analysis or functional neuroimaging techniques, such as arterial spin labeling, in operationally defined cases and a comparison group chosen to minimize selection bias remains the ideal research design, and longitudinal studies assessing the stability of neuroimaging abnormalities in catatonia will also be important.

Footnote

Ms. Jeyaventhan and Ms. Thanikasalam contributed equally to this work.

Supplementary Material

File (appi.neuropsych.21070181.ds001.pdf)

References

1.
Fink M, Taylor MA: The catatonia syndrome: forgotten but not gone. Arch Gen Psychiatry 2009; 66:1173–1177
2.
Solmi M, Pigato GG, Roiter B, et al: Prevalence of catatonia and its moderators in clinical samples: results from a meta-analysis and meta-regression analysis. Schizophr Bull 2018; 44:1133–1150
3.
Carroll BT, Mendenhall B, Appiani F, et al: Catatonia due to a general medical condition (organic catatonia). Curr Psychiatry Rev 2013; 9:105–110
4.
van der Heijden FMMA, Tuinier S, Arts NJM, et al: Catatonia: disappeared or under-diagnosed? Psychopathology 2005; 38:3–8
5.
Reed GM, First MB, Kogan CS, et al: Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. World Psychiatry 2019; 18:3–19
6.
Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA, American Psychiatric Association, 2013
7.
Bush G, Fink M, Petrides G, et al: Catatonia: II. treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand 1996; 93:137–143
8.
Van Duppen Z, Sienaert P: Closing up: the phenomenology of catatonia; in Time and Body:  Phenomenological and Psychopathological Approaches. Edited by Tewes C, Stanghellini G. Cambridge, United Kingdom, Cambridge University Press, 2020
9.
Rogers JP, Pollak TA, Blackman G, et al: Catatonia and the immune system: a review. Lancet Psychiatry 2019; 6:620–63
10.
Fricchione G, Beach S: Cingulate-basal ganglia-thalamo-cortical aspects of catatonia and implications for treatment. Handb Clin Neurol 2019; 166:223–252
11.
Walther S, Strik W: Motor symptoms and schizophrenia. Neuropsychobiology 2012; 66:77–92
12.
Northoff G: What catatonia can tell us about “top-down modulation”: a neuropsychiatric hypothesis. Behav Brain Sci 2002; 25:555–577
13.
Daniels J: Catatonia: clinical aspects and neurobiological correlates. J Neuropsychiatry Clin Neurosci 2009; 21:371–380
14.
Caroff SN, Mann SC, Francis A, et al. (eds): Catatonia: From Psychopathology to Neurobiology. Washington, DC, American Psychiatric Publishing, 2004
15.
Haroche A, Rogers J, Plaze M, et al: Brain imaging in catatonia: systematic review and directions for future research. Psychol Med 2020; 50:1585–1597
16.
Stewart R, Soremekun M, Perera G, et al: The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data. BMC Psychiatry (Epub, Aug 12, 2009)
17.
Bush G, Fink M, Petrides G, et al: Catatonia: I. rating scale and standardized examination. Acta Psychiatr Scand 1996; 93:129–136
18.
Nunes ALS, Filgueiras A, Nicolato R, et al: Development and validation of the Bush-Francis Catatonia Rating Scale–Brazilian version. Arq Neuropsiquiatr 2017; 75:44–49
19.
Rogers JP, Pollak TA, Begum N, et al: Catatonia: demographic, clinical and laboratory associations. Psychol Med (Epub ahead of print, Nov 2, 2021)
20.
Gunning-Dixon FM, Brickman AM, Cheng JC, et al: Aging of cerebral white matter: a review of MRI findings. Int J Geriatr Psychiatry 2009; 24:109–117
21.
Nasrallah HA, Schwarzkopf SB, Olson SC, et al: Gender differences in schizophrenia on MRI brain scans. Schizophr Bull 1990; 16:205–210
22.
Choi YY, Lee JJ, Choi KY, et al: The aging slopes of brain structures vary by ethnicity and sex: evidence from a large magnetic resonance imaging dataset from a single scanner of cognitively healthy elderly people in Korea. Front Aging Neurosci 2020; 12:233
23.
Liu G, Allen B, Lopez O, et al: Racial differences in gray matter integrity by diffusion tensor in black and white octogenarians. Curr Alzheimer Res 2015; 12:648–654
24.
Debette S, Schilling S, Duperron M-G, et al: Clinical significance of magnetic resonance imaging markers of vascular brain injury: a systematic review and meta-analysis. JAMA Neurol 2019; 76:81–94
25.
Dutt A, Grover S, Chakrabarti S, et al: Phenomenology and treatment of Catatonia: a descriptive study from north India. Indian J Psychiatry 2011; 53:36–40
26.
Stöber G, Franzek E, Haubitz I, et al: Gender differences and age of onset in the catatonic subtypes of schizophrenia. Psychopathology 1998; 31:307–312
27.
Hutchinson G, Takei N, Sham P, et al: Factor analysis of symptoms in schizophrenia: differences between White and Caribbean patients in Camberwell. Psychol Med 1999; 29:607–612
28.
Smith JH, Smith VD, Philbrick KL, et al: Catatonic disorder due to a general medical or psychiatric condition. J Neuropsychiatry Clin Neurosci 2012; 24:198–207
29.
Ethnic Group, National Identity and Religion. London, Office for National Statistics, 2011. https://www.ons.gov.uk/methodology/classificationsandstandards/measuringequality/ethnicgroupnationalidentityandreligion
30.
von Elm E, Altman DG, Egger M, et al: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147:573–577
31.
Chua SE, McKenna PJ: Schizophrenia—a brain disease? A critical review of structural and functional cerebral abnormality in the disorder. Br J Psychiatry 1995; 166:563–582
32.
Rego T, Velakoulis D: Brain imaging in psychiatric disorders: target or screen? BJPsych Open 2019; 5:e4
33.
Mueller C, Rufer M, Moergeli H, et al: Brain imaging in psychiatry—a study of 435 psychiatric in-patients at a university clinic. Acta Psychiatr Scand 2006; 114:91–100
34.
Medda P, Toni C, Luchini F, et al: Catatonia in 26 patients with bipolar disorder: clinical features and response to electroconvulsive therapy. Bipolar Disord 2015; 17:892–901
35.
Joseph AB, Anderson WH, O’Leary DH: Brainstem and vermis atrophy in catatonia. Am J Psychiatry 1985; 142:352–354
36.
Hirjak D, Rashidi M, Kubera KM, et al: Multimodal magnetic resonance imaging data fusion reveals distinct patterns of abnormal brain structure and function in catatonia. Schizophr Bull 2020; 46:202–210
37.
Wilcox JA: Cerebellar atrophy and catatonia. Biol Psychiatry 1991; 29:733–734
38.
Falkenberg I, Benetti S, Raffin M, et al: Clinical utility of magnetic resonance imaging in first-episode psychosis. Br J Psychiatry 2017; 211:231–237

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 386 - 392
PubMed: 35414194

History

Received: 16 July 2021
Revision received: 16 October 2021
Accepted: 25 October 2021
Published online: 13 April 2022
Published in print: Fall 2022

Keywords

  1. catatonia
  2. neuroimaging
  3. MRI
  4. atrophy
  5. neuroradiology
  6. lesion

Authors

Details

Roshell Jeyaventhan, B.Sc.
Faculty of Life Sciences and Medicine, King's College London, London (Jeyaventhan, Thanikasalam); Department of Neuroimaging (Mehta) and Department of Psychosis Studies (Pollak, Nicholson, Kolliakou), Institute of Psychiatry Psychology and Neuroscience, King's College London, London; Division of Psychiatry (Solmi, Lewis, Rogers), Queen Square Institute of Neurology (Zandi), and Institute of Mental Health (David), University College London, London; University College London Hospitals NHS Foundation Trust, London (Zandi); South London and Maudsley Mental Health NHS Trust, London (Pritchard, Jewell, Rogers); Psychiatrie and Neurosciences, Le Groupe Hospitalier Universitaire Paris, Paris (Haroche); CHRU de Lille Pôle Psychiatrie Médecine Légale et Médecine en Milieu Pénitentiaire, Lille, France (Amad).
Ramya Thanikasalam, B.Sc.
Faculty of Life Sciences and Medicine, King's College London, London (Jeyaventhan, Thanikasalam); Department of Neuroimaging (Mehta) and Department of Psychosis Studies (Pollak, Nicholson, Kolliakou), Institute of Psychiatry Psychology and Neuroscience, King's College London, London; Division of Psychiatry (Solmi, Lewis, Rogers), Queen Square Institute of Neurology (Zandi), and Institute of Mental Health (David), University College London, London; University College London Hospitals NHS Foundation Trust, London (Zandi); South London and Maudsley Mental Health NHS Trust, London (Pritchard, Jewell, Rogers); Psychiatrie and Neurosciences, Le Groupe Hospitalier Universitaire Paris, Paris (Haroche); CHRU de Lille Pôle Psychiatrie Médecine Légale et Médecine en Milieu Pénitentiaire, Lille, France (Amad).
Mitul A. Mehta, Ph.D.
Faculty of Life Sciences and Medicine, King's College London, London (Jeyaventhan, Thanikasalam); Department of Neuroimaging (Mehta) and Department of Psychosis Studies (Pollak, Nicholson, Kolliakou), Institute of Psychiatry Psychology and Neuroscience, King's College London, London; Division of Psychiatry (Solmi, Lewis, Rogers), Queen Square Institute of Neurology (Zandi), and Institute of Mental Health (David), University College London, London; University College London Hospitals NHS Foundation Trust, London (Zandi); South London and Maudsley Mental Health NHS Trust, London (Pritchard, Jewell, Rogers); Psychiatrie and Neurosciences, Le Groupe Hospitalier Universitaire Paris, Paris (Haroche); CHRU de Lille Pôle Psychiatrie Médecine Légale et Médecine en Milieu Pénitentiaire, Lille, France (Amad).
Francesca Solmi, Ph.D.
Faculty of Life Sciences and Medicine, King's College London, London (Jeyaventhan, Thanikasalam); Department of Neuroimaging (Mehta) and Department of Psychosis Studies (Pollak, Nicholson, Kolliakou), Institute of Psychiatry Psychology and Neuroscience, King's College London, London; Division of Psychiatry (Solmi, Lewis, Rogers), Queen Square Institute of Neurology (Zandi), and Institute of Mental Health (David), University College London, London; University College London Hospitals NHS Foundation Trust, London (Zandi); South London and Maudsley Mental Health NHS Trust, London (Pritchard, Jewell, Rogers); Psychiatrie and Neurosciences, Le Groupe Hospitalier Universitaire Paris, Paris (Haroche); CHRU de Lille Pôle Psychiatrie Médecine Légale et Médecine en Milieu Pénitentiaire, Lille, France (Amad).
Thomas A. Pollak, Ph.D.
Faculty of Life Sciences and Medicine, King's College London, London (Jeyaventhan, Thanikasalam); Department of Neuroimaging (Mehta) and Department of Psychosis Studies (Pollak, Nicholson, Kolliakou), Institute of Psychiatry Psychology and Neuroscience, King's College London, London; Division of Psychiatry (Solmi, Lewis, Rogers), Queen Square Institute of Neurology (Zandi), and Institute of Mental Health (David), University College London, London; University College London Hospitals NHS Foundation Trust, London (Zandi); South London and Maudsley Mental Health NHS Trust, London (Pritchard, Jewell, Rogers); Psychiatrie and Neurosciences, Le Groupe Hospitalier Universitaire Paris, Paris (Haroche); CHRU de Lille Pôle Psychiatrie Médecine Légale et Médecine en Milieu Pénitentiaire, Lille, France (Amad).
Timothy R. Nicholson, Ph.D.
Faculty of Life Sciences and Medicine, King's College London, London (Jeyaventhan, Thanikasalam); Department of Neuroimaging (Mehta) and Department of Psychosis Studies (Pollak, Nicholson, Kolliakou), Institute of Psychiatry Psychology and Neuroscience, King's College London, London; Division of Psychiatry (Solmi, Lewis, Rogers), Queen Square Institute of Neurology (Zandi), and Institute of Mental Health (David), University College London, London; University College London Hospitals NHS Foundation Trust, London (Zandi); South London and Maudsley Mental Health NHS Trust, London (Pritchard, Jewell, Rogers); Psychiatrie and Neurosciences, Le Groupe Hospitalier Universitaire Paris, Paris (Haroche); CHRU de Lille Pôle Psychiatrie Médecine Légale et Médecine en Milieu Pénitentiaire, Lille, France (Amad).
Megan Pritchard, M.Sc.
Faculty of Life Sciences and Medicine, King's College London, London (Jeyaventhan, Thanikasalam); Department of Neuroimaging (Mehta) and Department of Psychosis Studies (Pollak, Nicholson, Kolliakou), Institute of Psychiatry Psychology and Neuroscience, King's College London, London; Division of Psychiatry (Solmi, Lewis, Rogers), Queen Square Institute of Neurology (Zandi), and Institute of Mental Health (David), University College London, London; University College London Hospitals NHS Foundation Trust, London (Zandi); South London and Maudsley Mental Health NHS Trust, London (Pritchard, Jewell, Rogers); Psychiatrie and Neurosciences, Le Groupe Hospitalier Universitaire Paris, Paris (Haroche); CHRU de Lille Pôle Psychiatrie Médecine Légale et Médecine en Milieu Pénitentiaire, Lille, France (Amad).
Amelia Jewell, M.Sc.
Faculty of Life Sciences and Medicine, King's College London, London (Jeyaventhan, Thanikasalam); Department of Neuroimaging (Mehta) and Department of Psychosis Studies (Pollak, Nicholson, Kolliakou), Institute of Psychiatry Psychology and Neuroscience, King's College London, London; Division of Psychiatry (Solmi, Lewis, Rogers), Queen Square Institute of Neurology (Zandi), and Institute of Mental Health (David), University College London, London; University College London Hospitals NHS Foundation Trust, London (Zandi); South London and Maudsley Mental Health NHS Trust, London (Pritchard, Jewell, Rogers); Psychiatrie and Neurosciences, Le Groupe Hospitalier Universitaire Paris, Paris (Haroche); CHRU de Lille Pôle Psychiatrie Médecine Légale et Médecine en Milieu Pénitentiaire, Lille, France (Amad).
Anna Kolliakou, Ph.D.
Faculty of Life Sciences and Medicine, King's College London, London (Jeyaventhan, Thanikasalam); Department of Neuroimaging (Mehta) and Department of Psychosis Studies (Pollak, Nicholson, Kolliakou), Institute of Psychiatry Psychology and Neuroscience, King's College London, London; Division of Psychiatry (Solmi, Lewis, Rogers), Queen Square Institute of Neurology (Zandi), and Institute of Mental Health (David), University College London, London; University College London Hospitals NHS Foundation Trust, London (Zandi); South London and Maudsley Mental Health NHS Trust, London (Pritchard, Jewell, Rogers); Psychiatrie and Neurosciences, Le Groupe Hospitalier Universitaire Paris, Paris (Haroche); CHRU de Lille Pôle Psychiatrie Médecine Légale et Médecine en Milieu Pénitentiaire, Lille, France (Amad).
Ali Amad, M.D., Ph.D.
Faculty of Life Sciences and Medicine, King's College London, London (Jeyaventhan, Thanikasalam); Department of Neuroimaging (Mehta) and Department of Psychosis Studies (Pollak, Nicholson, Kolliakou), Institute of Psychiatry Psychology and Neuroscience, King's College London, London; Division of Psychiatry (Solmi, Lewis, Rogers), Queen Square Institute of Neurology (Zandi), and Institute of Mental Health (David), University College London, London; University College London Hospitals NHS Foundation Trust, London (Zandi); South London and Maudsley Mental Health NHS Trust, London (Pritchard, Jewell, Rogers); Psychiatrie and Neurosciences, Le Groupe Hospitalier Universitaire Paris, Paris (Haroche); CHRU de Lille Pôle Psychiatrie Médecine Légale et Médecine en Milieu Pénitentiaire, Lille, France (Amad).
Alexandre Haroche, M.D.
Faculty of Life Sciences and Medicine, King's College London, London (Jeyaventhan, Thanikasalam); Department of Neuroimaging (Mehta) and Department of Psychosis Studies (Pollak, Nicholson, Kolliakou), Institute of Psychiatry Psychology and Neuroscience, King's College London, London; Division of Psychiatry (Solmi, Lewis, Rogers), Queen Square Institute of Neurology (Zandi), and Institute of Mental Health (David), University College London, London; University College London Hospitals NHS Foundation Trust, London (Zandi); South London and Maudsley Mental Health NHS Trust, London (Pritchard, Jewell, Rogers); Psychiatrie and Neurosciences, Le Groupe Hospitalier Universitaire Paris, Paris (Haroche); CHRU de Lille Pôle Psychiatrie Médecine Légale et Médecine en Milieu Pénitentiaire, Lille, France (Amad).
Glyn Lewis, Ph.D.
Faculty of Life Sciences and Medicine, King's College London, London (Jeyaventhan, Thanikasalam); Department of Neuroimaging (Mehta) and Department of Psychosis Studies (Pollak, Nicholson, Kolliakou), Institute of Psychiatry Psychology and Neuroscience, King's College London, London; Division of Psychiatry (Solmi, Lewis, Rogers), Queen Square Institute of Neurology (Zandi), and Institute of Mental Health (David), University College London, London; University College London Hospitals NHS Foundation Trust, London (Zandi); South London and Maudsley Mental Health NHS Trust, London (Pritchard, Jewell, Rogers); Psychiatrie and Neurosciences, Le Groupe Hospitalier Universitaire Paris, Paris (Haroche); CHRU de Lille Pôle Psychiatrie Médecine Légale et Médecine en Milieu Pénitentiaire, Lille, France (Amad).
Michael S. Zandi, Ph.D.
Faculty of Life Sciences and Medicine, King's College London, London (Jeyaventhan, Thanikasalam); Department of Neuroimaging (Mehta) and Department of Psychosis Studies (Pollak, Nicholson, Kolliakou), Institute of Psychiatry Psychology and Neuroscience, King's College London, London; Division of Psychiatry (Solmi, Lewis, Rogers), Queen Square Institute of Neurology (Zandi), and Institute of Mental Health (David), University College London, London; University College London Hospitals NHS Foundation Trust, London (Zandi); South London and Maudsley Mental Health NHS Trust, London (Pritchard, Jewell, Rogers); Psychiatrie and Neurosciences, Le Groupe Hospitalier Universitaire Paris, Paris (Haroche); CHRU de Lille Pôle Psychiatrie Médecine Légale et Médecine en Milieu Pénitentiaire, Lille, France (Amad).
Anthony S. David, M.D.
Faculty of Life Sciences and Medicine, King's College London, London (Jeyaventhan, Thanikasalam); Department of Neuroimaging (Mehta) and Department of Psychosis Studies (Pollak, Nicholson, Kolliakou), Institute of Psychiatry Psychology and Neuroscience, King's College London, London; Division of Psychiatry (Solmi, Lewis, Rogers), Queen Square Institute of Neurology (Zandi), and Institute of Mental Health (David), University College London, London; University College London Hospitals NHS Foundation Trust, London (Zandi); South London and Maudsley Mental Health NHS Trust, London (Pritchard, Jewell, Rogers); Psychiatrie and Neurosciences, Le Groupe Hospitalier Universitaire Paris, Paris (Haroche); CHRU de Lille Pôle Psychiatrie Médecine Légale et Médecine en Milieu Pénitentiaire, Lille, France (Amad).
Jonathan P. Rogers, M.R.C.Psych. [email protected]
Faculty of Life Sciences and Medicine, King's College London, London (Jeyaventhan, Thanikasalam); Department of Neuroimaging (Mehta) and Department of Psychosis Studies (Pollak, Nicholson, Kolliakou), Institute of Psychiatry Psychology and Neuroscience, King's College London, London; Division of Psychiatry (Solmi, Lewis, Rogers), Queen Square Institute of Neurology (Zandi), and Institute of Mental Health (David), University College London, London; University College London Hospitals NHS Foundation Trust, London (Zandi); South London and Maudsley Mental Health NHS Trust, London (Pritchard, Jewell, Rogers); Psychiatrie and Neurosciences, Le Groupe Hospitalier Universitaire Paris, Paris (Haroche); CHRU de Lille Pôle Psychiatrie Médecine Légale et Médecine en Milieu Pénitentiaire, Lille, France (Amad).

Notes

Send correspondence to Dr. Rogers ([email protected]).

Competing Interests

The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. The funders played no part in the design or conduct of the study, or in the decision to publish.

Funding Information

This study represents independent research partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley National Health Service (NHS) Foundation Trust and King’s College London. This research was also funded by the Wellcome Trust (grant 220659/Z/20/Z). The accepted manuscript version of this article is available at the University College London Research Publications Service under a CC-BY license in accordance with Open Access principles. Dr. Pollak is supported by an NIHR Clinical Lectureship. Ms. Pritchard and Dr. Kolliakou are partly funded by the NIHR Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King’s College London. Drs. Lewis, Zandi, and David are supported by the NIHR University College London Hospitals Biomedical Research Centre. Dr. Rogers is supported by an NIHR Academic Clinical Fellowship (ACF-2016-17-007) and a Wellcome Trust Ph.D. Training Fellowship for Clinicians (220659/Z/20/Z). Dr. Zandi is supported by the National Brain Appeal.Dr. Mehta reports receipt of grant funding from H. Lundbeck A/S and Sosei Heptares. Dr. Zandi reports receipt of personal fees from UCB Pharma for lecturing. The other authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share